It may well be that the coming (and to some extent existing) revolution in genetically individualized medical therapy will require changes in how drugs are evaluated, labeled, etc., but this is a singularity - driven issue that needs to be addressed by the policy branches of our government, and not
haphazardly in product liability litigation.